The DOI matches its Crossref record; 511 of the 514 references it cites were found in a registry or an index; 260 of the 474 sources its claims cite were checked for support.
Major depressive disorder: hypothesis, mechanism, prevention and treatment
Open accessAbstract
Worldwide, the incidence of major depressive disorder (MDD) is increasing annually, resulting in greater economic and social burdens. Moreover, the pathological mechanisms of MDD and the mechanisms underlying the effects of pharmacological treatments for MDD are complex and unclear, and additional diagnostic and therapeutic strategies for MDD still are needed. The currently widely accepted theories of MDD pathogenesis include the neurotransmitter and receptor hypothesis, hypothalamic-pituitary-adrenal (HPA) axis hypothesis, cytokine hypothesis, neuroplasticity hypothesis and systemic influence hypothesis, but these hypothesis cannot completely explain the pathological mechanism of MDD. Even it is still hard to adopt only one hypothesis to completely reveal the pathogenesis of MDD, thus in recent years, great progress has been made in elucidating the roles of multiple organ interactions in the pathogenesis MDD and identifying novel therapeutic approaches and multitarget modulatory strategies, further revealing the disease features of MDD. Furthermore, some newly discovered potential pharmacological targets and newly studied antidepressants have attracted widespread attention, some reagents have even been approved for clinical treatment and some novel therapeutic methods such as phototherapy and acupuncture have been discovered to have effective improvement for the depressive symptoms. In this work, we comprehensively summarize the latest research on the pathogenesis and diagnosis of MDD, preventive approaches and therapeutic medicines, as well as the related clinical trials.
Overview
CoChat Summary
TL;DR
MDD is a heterogeneous, highly prevalent disorder whose pathogenesis is not fully explained by any single hypothesis; the review synthesizes evidence for monoamine, HPA-axis, inflammatory, genetic/epigenetic, brain-remodeling, and social-psychological mechanisms, with growing emphasis on astrocyte and multi-organ involvement. It also surveys diagnostic biomarkers, prevention strategies, and pharmacological and nonpharmacological treatments, noting that current antidepressants leave a substantial proportion of patients without remission.
Key findings
- MDD affects about 300 million people worldwide; it ranked third in disease burden in 2018 and is predicted to rank first by 2030. Heritability is estimated at 30–50%, and GWAS have identified 178 genetic risk loci and over 200 candidate genes, though no single genetic variation has been found to increase MDD risk.
- Women have approximately twice the incidence of MDD as men. In 2018, comorbid disorders rather than MDD itself accounted for 63% of all MDD-related costs in the United States.
- Multiple interacting mechanisms are implicated, including monoamine deficiency (5-HT, DA, NE), HPA-axis hyperactivity and glucocorticoid/GR signaling, proinflammatory cytokines (IL-1β, TNF-α, IL-6), oxidative stress, NLRP3 inflammasome activation, reduced BDNF, and astrocytic marker changes (Cx30/43, GFAP, AQP4, S100B).
- In a 1-year follow-up, clinically significant worsening of depressive symptoms occurred in 44% of untreated patients versus 38% with circadian rhythm support (CRS), 28% with cognitive behavioral therapy for insomnia (CBT-I), and 9% with CBT-I + CRS. Even after multiple treatment attempts, almost 30% of MDD patients do not experience remission.
Methods
- Narrative review summarizing recent research on MDD etiology, pathogenesis, diagnosis, prevention, mechanisms, and pharmacological and nonpharmacological treatment, including related clinical experiments.
- Evidence discussed includes human postmortem tissue studies, transcriptomic and multiomics analyses, clinical imaging (MRI, R-fMRI, PET with SV2A radioligand), serum biomarker studies, randomized controlled trials, meta-analyses, and animal models such as CUMS, CUMR, CURD, CSDS, and LPS- or stress-induced depression models.
- No systematic review, meta-analysis, or primary data collection is described; the paper synthesizes and organizes findings across hypotheses and treatment categories.
Limitations
- Stated in the paper: the etiology of MDD remains unclear; no single hypothesis fully explains its pathological basis; diagnostic criteria are subjective and lack characteristic symptoms or objective diagnostic evidence; animal models of MDD and other mental diseases are lacking; most cellular and structural alterations cannot be consistently observed in vivo; existing theories cannot completely explain why almost 30% of patients do not remit after multiple treatments.
- Evident from the text: as a narrative review, it does not describe a systematic literature search, inclusion/exclusion criteria, or formal quality appraisal of the cited studies.
- Evident from the text: many proposed mechanisms and biomarkers are described as promising but not yet validated for clinical diagnosis or treatment, and the review notes inconsistent neuroimaging findings and controversy over some markers such as serum GFAP.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
212 Valid · 21 Not valid · 143 Not checked · 25 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However, no single genetic variation has been found to increase the risk of MDD thus far. 26”
What the sources say
- Disputedcites [26] Kendall, K. M. et al. The genetic basis of major depression. Psychol. Med. 51, 2217–2230 (2021). sourceExperimental — accuracy not yet measured
The GWAS discussion (p. 16) says that two significant loci near SIRT1 and LHPP were identified and replicated in Han Chinese patients with recurrent MDD. It also describes European depression risk SNPs and 178 risk loci in Europeans. The paper distinguishes these findings from its narrower statement (p. 10) that a sequencing study found no association for individual rare or low-frequency variants. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Global topological E/I imbalance in MDD is discovered through gene and protein expression of molecules related to inhibitory GABAergic and excitatory glutamatergic signaling in the postmortem MDD brains. 22 , 208 , 209”
What the sources say
- Partly supportedcites [22] Sequeira, A. et al. Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. PLoS ONE 4, e6585 (2009). sourceExperimental — accuracy not yet measured
The Results (Pathways globally differentially expressed; page not provided) report altered expression of GABAergic and glutamatergic genes across brain regions in people who died by suicide with major depression. The paper does not establish a global topological excitation–inhibition imbalance or report protein-expression measurements; its Methods describe RNA-based expression analysis. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [208] Hu, Y. T., Tan, Z. L., Hirjak, D. & Northoff, G. Brain-wide changes in excitation-inhibition balance of major depressive disorder: a systematic review of topographic patterns of GABA- and glutamatergic alterations. Mol. Psychiatry 28, 3257–3266 (2023). source
- Disputedcites [209] Zhao, J. et al. Prefrontal alterations in GABAergic and glutamatergic gene expression in relation to depression and suicide. J. Psychiatr. Res. 102, 261–274 (2018). sourceExperimental — accuracy not yet measured
The Discussion (p. 11) says that glutamatergic and GABAergic mRNA expression changed similarly, leaving it unclear whether the overall excitation–inhibition balance was disturbed. The Results (p. 6) report gene-expression changes in two prefrontal regions, not a discovered global topological imbalance or a measurement of protein expression. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In individuals with MDD, aerobic exercise was found to be beneficial in ameliorating depressive symptoms, particularly in those with more severe depressive symptoms and a higher baseline RewP. 325 , 326”
What the sources say
- Not checked — no full text of the sourcecites [325] Brush, C. J. et al. A randomized trial of aerobic exercise for major depression: examining neural indicators of reward and cognitive control as predictors and treatment targets. Psychol. Med. 52, 893–903 (2022). source
- Disputedcites [326] Kujawa, A. et al. Reduced reward responsiveness predicts change in depressive symptoms in anxious children and adolescents following treatment. J. Child Adolesc. Psychopharmacol. 29, 378–385 (2019). sourceExperimental — accuracy not yet measured
The Results (page unavailable) report that a reduced—not higher—baseline RewP predicted greater improvement in depressive symptoms. The study examined anxious children and adolescents treated with CBT or SSRIs, not aerobic exercise in individuals with MDD; it also does not establish that those with more severe baseline symptoms benefited more. (LLM, conf=0.82)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Specifically, increasing evidence suggests that astrocytic dysfunction plays a substantial role in MDD. 17”
What the sources say
- Supportedcites [17] Zhou, X. et al. Astrocyte, a promising target for mood disorder interventions. Front. Mol. Neurosci. 12, 136 (2019). source
The Introduction says abnormal astrocyte function may contribute to mood-disorder pathophysiology, with particular emphasis on depression. The Human Data section reports altered astrocyte-related gene and protein expression in patients with depression and MDD. Together, these passages support the claim’s hedged description of a substantial role in MDD; page numbers were not provided. (LLM, conf=0.92)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Recent family, twin, and adoption studies suggests that genetic factors play a crucial role in the occurrence of MDD. 25”
What the sources say
- Supportedcites [25] Lohoff, F. W. Overview of the genetics of major depressive disorder. Curr. Psychiatry Rep. 12, 539–546 (2010). source
The Introduction states that genetic factors play important roles in the development of MDD, as indicated by family, twin, and adoption studies. The Twin and Family Studies section likewise says these study types consistently document a genetic component. (LLM, conf=0.94)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
189 more claims · 106 with their cited sources checked
Create a free account to see all 401 claims and every source verdict.
- It may state two separate claims as one. 178
- Probably not a substantial claim. 47
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent studies have revealed a close relationship between gut microbiota and mood disorders, drawing increasing attention to the role of gut microbial communities in the onset and progression of these mood disorders [5,6].”
From The Impact of Weizmannia coagulans BC99 on Anxiety and Depression: An 8-Week Clinical Pilot Study Through the Gut Microbiota–Brain Axis (2025) · cites this paper as [6]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“SD is found to reduce BDNF levels and induce depressive-like behaviors in the sorted astrocytes from GFAP-GFP transgenic mice by activating the NLRP3 inflammasome.”
“chronic SD can specifically activate the NLRP3 inflammasome and decrease the level of BDNF in astrocytes to ameliorate depressive-like behaviors.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Estrogen therapy can decrease the quantity of 5-HT 1 and β-adrenergic receptors”
“while increasing the quantity of 5-HT 1 receptors.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Over 100 gene loci, including those associated with presynaptic vesicle trafficking (PCLO), dopaminergic neurotransmission (a primary target of antipsychotics), glutamate ionotropic receptor kainate type subunit 5 (GRIK5), and metabotropic glutamate receptor 5 (GRM5), and neuronal calcium signaling such as calcium voltage-gated channel subunit alpha1 E (CACNA1E) and calcium voltage-gated channel auxiliary subunit alpha2 delta1”
“However, no single genetic variation has been found to increase the risk of MDD thus far.”
Citations
Cites
James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32279-7 · Cited by 13,867
RNA-Seq: a revolutionary tool for transcriptomics
Wang, Z., Gerstein, M., & Snyder, M. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2484 · Cited by 13,174
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Scoville, W. B. (1949) · Journal of neurosurgery · doi:10.3171/jns.1949.6.1.0065 · Cited by 7,380
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729 · cited 1×
“312,313 317 – 319 Furthermore, physical exercise for approximately 45 minutes per day can signi fi cantly reduce the risk of MDD. 320,321 High-intensity activity, such as aerobic exercise, dancing, and the usage of exercise machines, and low-intensity exercises, including yoga and stretching, can…”
BackgroundMalhi, G. S., & Mann, J. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31948-2 · Cited by 4,099
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 1×
“375 Due to the rapid antidepressant effects of ketamine, unlike the delayed effects of traditional antidepressant drugs, 376 research on this drug has continued and has revealed its mechanisms of action and potential drug targets.”
BackgroundGut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622 · cited 1×
“241 Alterations in the gut microbiota and in fl ammatory agents have an impact on the KYN pathway, metabolism, and toxin metabolism in the periphery.”
BackgroundeQTLGen, Wray, N. R., 23andMe, the Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, Ripke, S., Mattheisen, M., Trzaskowski, M., Byrne, E. M., Abdellaoui, A., Adams, M. J., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0090-3 · Cited by 3,005 · cited 2×
“19,27,28 In addition, rare copy number variants are also identi fi ed to be related to MDD risk, there may be three copy number variants (CNV) loci associated with Prader-Willis syndrome: 1q21.”
Cited by
PI3K/AKT signaling pathway: Molecular mechanisms and therapeutic potential in depression
Guo, N., Wang, X., Xu, M., Bai, J., Yu, H., & Zhang, L. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107300 · Cited by 218
Vagus nerve stimulation (VNS): recent advances and future directions
Austelle, C. W., Cox, S. S., Wills, K. E., & Badran, B. W. (2024) · Clinical Autonomic Research · doi:10.1007/s10286-024-01065-w · Cited by 147
“For example, major depression is associated with alterations in the brain and periphery, including immune and endocrine dysfunction [21].”
BackgroundJiao, W., Lin, J., Deng, Y., Ji, Y., Liang, C., Wei, S., Xi, J., & Yan, F. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03312-3 · Cited by 140
Sharma, S., Chawla, S., Kumar, P., Ahmad, R., & Verma, P. K. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149123 · Cited by 107
Kalogerakou, T., & Αντωνιάδου, Μ. (2024) · Antioxidants · doi:10.3390/antiox13121508 · Cited by 124
Metadata
- Authors
- Cui, L., Li, S., Wang, S., Wu, X., Liu, Y., Yu, W., Wang, Y., Tang, Y., Xia, M., & Li, B.
- Affiliations
- China Medical University (CN)
- Chengdu University (CN)
- First Hospital of China Medical University (CN)
- Corresponding author
- Xia, Maosheng
- Li, Baoman
- ORCID
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-02-09
- Volume
- 9
- Issue
- 1
- Pages
- 30-30
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC10853571
- OpenAlex
- W4392731282
- Semantic Scholar
- e69e2e42bcc9396c4df790e7a320846a0aa10211
- Cited by
- 1,244
- References
- 514
- Citations by year
- 2026: 536 · 2025: 570 · 2024: 138
- FWCI
- 60.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Natural Science Foundation of China (81871852, 32271038)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- major depressive disorder, pathogenesis, neurotransmitter hypothesis, hypothalamic-pituitary-adrenal axis, neuroplasticity, antidepressants, therapeutic target, phototherapy, acupuncture, depression prevention, depression diagnosis
- MeSH terms
- Major Depressive Disorder, Humans, Hypothalamo-Hypophyseal System, Pituitary-Adrenal System
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Major depressive disorder: hypothesis, mechanism, prevention and treatment. https://app.cochat.ai/papers/10.1038/s41392-024-01738-y
- The paper
- Cui, L., Li, S., Wang, S., Wu, X., Liu, Y., Yu, W., Wang, Y., Tang, Y., Xia, M., & Li, B. (2024). Major depressive disorder: hypothesis, mechanism, prevention and treatment. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-024-01738-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.